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Abstract
Priming immunization plays a key role in protecting individuals or populations to influenza viruses that are novel to
humans. To identify the most promising vaccine priming strategy, we have evaluated different prime-boost regimens using
inactivated, DNA and live attenuated vaccines in ferrets. Live attenuated influenza A/Vietnam/1203/2004 (H5N1) candidate
vaccine (LAIV, VN04 ca) primed ferrets efficiently while inactivated H5N1 vaccine could not prime the immune response in
seronegative ferrets unless an adjuvant was used. However, the H5 HA DNA vaccine alone was as successful as an
adjuvanted inactivated VN04 vaccine in priming the immune response to VN04 ca virus. The serum antibody titers of ferrets
primed with H5 HA DNA followed by intranasal vaccination of VN04 ca virus were comparable to that induced by two doses
of VN04 ca virus. Both LAIV-LAIV and DNA-LAIV vaccine regimens could induce antibody responses that cross-neutralized
antigenically distinct H5N1 virus isolates including A/HongKong/213/2003 (HK03) and prevented nasal infection of HK03
vaccine virus. Thus, H5 HA DNA vaccination may offer an alternative option for pandemic preparedness.
Citation: Suguitan AL Jr, Cheng X, Wang W, Wang S, Jin H, et al. (2011) Influenza H5 Hemagglutinin DNA Primes the Antibody Response Elicited by the Live
Attenuated Influenza A/Vietnam/1203/2004 Vaccine in Ferrets. PLoS ONE 6(7): e21942. doi:10.1371/journal.pone.0021942
Editor: Stephen Mark Tompkins, University of Georgia, United States of America
Received April 27, 2011; Accepted June 13, 2011; Published July 8, 2011
Copyright:  2011 Suguitan Jr et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by NIH/NIAID grant AI078073. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript. No additional external funding received for this study.
Competing Interests: The authors are employees of MedImmune company. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing
data and materials..
* E-mail: jinh@medimmune.com
Introduction
Influenza pandemics of varying severities have occurred in the
last century. The 1918 ‘‘Spanish flu’’ (H1N1) that claimed the lives
of about 40 million people is perhaps one of the deadliest
pandemics in history [1]. The 1957 ‘‘Asian flu’’ (H2N2) and the
1968 ‘‘Hong Kong flu’’ (H3N2) pandemics are believed to have
been caused by viruses from reassortment of circulating human
strains and avian viruses [2]. The recent emergence of the swine-
origin influenza A H1N1 pandemic (pH1N1) virus is a sober
reminder that viruses with novel antigenic properties can infect
and spread among an immunologically naı ¨ve human population
with potentially devastating consequences.
Among the avian influenza viruses that have sporadically
infected humans, highly pathogenic avian influenza (HPAI) H5N1
viruses pose the greatest threat due to their high virulence. As of
February 2011, there have been 525 laboratory-confirmed cases of
H5N1 infection, resulting in 310 deaths (,59% mortality) [3].
There are concerns that H5N1 viruses could evolve and adapt to
replicate and spread in the human population or gain human-to-
human transmissibility through reassortment with circulating
human influenza A viruses [4]. The 2009 pH1N1 virus has a
high genetic compatibility with an avian H5N1 virus, raising the
possibility that HPAI H5N1 viruses could acquire the ability of
being readily transmitted among individuals [5]. Thus, the
development of safe and efficacious vaccines against these viruses
is a public health priority.
Vaccination is an integral component of strategies aiming to
prevent and control pandemic influenza. Designed to mimic the
route of natural infection, live attenuated influenza virus (LAIV)
vaccines induce both local mucosal and systemic immunity [6] and
are able to elicit broad immune responses against antigenically
drifted strains [7,8,9,10]. An H5N1 LAIV vaccine was generated
by reverse genetics by combining the surface glycoprotein gene
segments of A/Vietnam/1203/2004 (H5N1, VN04) and the six
internal protein gene segments of the cold-adapted A/Ann Arbor/
6/60 (H2N2, AA ca) master donor vaccine strain that confer the
cold-adapted (ca), temperature-sensitive (ts), and attenuation (att)
phenotypes to the reassortant vaccine virus [11,12]. Our previous
pre-clinical studies showed that a single dose of VN04 ca elicited
low levels of neutralizing antibodies in mice and ferrets four weeks
after immunization. Although a single dose of VN04 ca completely
protected animals from challenge infection of lethal doses of
homologous and heterologous H5N1 wild-type (wt) viruses, two
doses of VN04 ca were required for complete protection from
pulmonary virus replication [12].
To prevent or control influenza pandemics caused by HPAI
H5N1 strains, multiple vaccinations or different vaccine prime
boost approaches might be needed. DNA vaccination with
plasmids expressing influenza viral proteins from the highly
variable hemagglutinin (HA) to the more conserved matrix and
nucleoprotein have been shown to induce humoral and cell-
mediated immune responses in various animal species [13,14,15].
Although DNA vaccination can induce antibody responses
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alone is not as efficient as an adjuvanted protein vaccine.
However, DNA vaccines could serve as a priming agent to
significantly increase the immunogenicity of a protein vaccine.
Such DNA prime-protein boost approach has been successfully
exploited to improve the breadth of the cellular and humoral
immune response elicited by various vaccines against different
bacterial and protozoan pathogens in animal studies
[17,18,19,20,21], as well as in an HIV vaccine study in humans
[22]. Wei et al. (2010) recently reported that H1 HA DNA priming
followed by a TIV boost not only led to increased neutralizing
antibody titers but also broadened the response to antigenically
distant H1N1 virus strains [23]. Huber et al. (2009) showed that
boosting H3 HA DNA-primed mice with H3N2 and PR8
reassortant viruses induced a robust and broad antibody response
against multiple H3N2 virus strains [24].
Since LAIV vaccination encourages development of a durable
mucosal immune response and robust cell-mediated immunity, we
evaluated several heterologous prime-boost regimens that would
augment the immunogenicity of live attenuated VN04 ca
candidate vaccine in ferrets. Our results indicate that an H5 HA
DNA vaccine successfully primed the immune response that was
subsequently boosted by VN04 ca virus. The protective immune
response induced by H5 HA DNA prime-VN04 ca virus boost is
comparable to that elicited by two doses of VN04 ca virus; both
regimens protected ferrets from an antigenically distinct H5N1
virus replication in the respiratory tract.
Results
Antibody response from LAIV and inactivated H5N1
protein vaccine regimen
An unadjuvanted inactivated VN04 (iVN04) monovalent
subvirion influenza vaccine was previously shown to be less
immunogenic in humans and requires a vaccine dose of 90 mgo f
HA antigen in multiple doses to induce an antibody response
similar to that of seasonal influenza vaccine [25,26]. As vaccine
supply will likely be limited during a pandemic, administering such
large quantities of antigen in multiple doses would be unrealistic
and inefficient. We therefore compared various prime-boost
strategies in seronegative ferrets using iVN04 and VN04 ca virus
to determine whether priming with either vaccine will be more
immunogenic than immunization with a single form of the vaccine
(Table 1). Ferrets primed with iVN04 did not have any detectable
serum neutralizing antibody titers (Nt Ab) 28 days post-
vaccination (Groups 2–4), but all ferrets primed with VN04 ca
virus had detectable levels of serum Nt Ab after the first dose
(Groups 5–7). The serum Nt Ab titers (51–62) elicited by a single
dose of VN04 ca virus reported in this study are slightly higher
than what was reported previously [12]. The Nt Ab titers in ferrets
that received only a single dose of VN04 ca virus declined from 51
to 20 at 8 weeks post-vaccination (Group 5). Vaccination of ferrets
with iVN04 adjuvanted with TiterMax, a stable water-in-oil
emulsion commonly used in animal studies, elicited serum Nt Ab
response (titer of 48) after the first dose and further increased to a
titer of 190 following a boost with VN04 ca virus (Group 8). Two
doses of iVN04 failed to induce any serum Nt Ab response (Group
3) due to lack of live virus priming in seronegative hosts [27].
Boosting of animals primed with iVN04 (Group 4), VN04 ca virus
(Group 6), or adjuvanted iVN04 (Group 8) induced higher serum
Nt Ab titers than that elicited by a single dose. However, iVN04 is
the least efficient in priming the antibody response (titer of 95 vs
160 or 190). The antibody response of VN04 ca virus-primed
ferrets was boosted with iVN04 without adujvant (Group 6). Due
to the small sample size of animals used in this study (n=4/group),
statistically significant differences in the geometric mean antibody
titers between different groups were not consistently achieved.
Despite this caveat, our data indicated that VN04 ca virus or
adjuvanted iVN04 vaccine can successfully prime seronegative
hosts to mount a higher immune response following boost with
VN04 ca virus or iVN04.
Expression of H5 HA protein from DNA
Since the use of a pandemic LAIV such as VN04 ca vaccine virus
prior to a pandemic may be restricted and iVN04 requires adjuvant
or a larger dose to prime the immune response against novel
influenza viruses, the prime-boost regimen of H5 HA DNA and
VN04 ca virus was thus considered for evaluation in ferrets. Our
previous studies showed that the HA antigens were expressed more
efficiently when the natural leader sequence was replaced with the
tPA leader sequence [28]. Thus, the H5 VN tPA DNA containing
tPA and codon-optimized HA cDNA including the ectodomain,
transmembrane domain and cytoplasmic tail (Figure 1A) was used
in the current study. The expression of H5 HA antigen from H5
DNA-transfected 293T cells was confirmed by Western blot
(Figure 1B). The HA protein remained cell-associated; no protein
wasdetected inthetransfectedcellculture supernatant.TheH5 HA
DNA vaccine contains multi-basic amino acid sequences at the
cleavage site between the HA1 and HA2 (PQREXRRKKRQG).
The expressed HA protein was cleaved to HA1 and HA2 in
addition to the HA0 in the transfected cells.
Antibody response from H5 HA DNA prime and H5N1
LAIV boost regimen
Serum antibody responses were measured by ELISA, HAI and
neutralization assays. Recombinant H5 HA-specific IgG and IgA
antibody titers were determined and presented in Figure 2. Very
low levels of HA-specific IgG antibody were detected in ferrets that
received the H5 HA DNA vaccine alone, even after the third dose
(Figure 2A) when the needle injection was used to deliver the DNA
vaccine. In contrast, ferrets that were primed with the H5 HA
DNA and boosted with VN04 ca virus reached a slightly higher
mean HA-specific IgG titer than ferrets that received two doses of
VN04 ca virus or VN04 ca virus prime-H5 HA DNA boost
Table 1. Ferret serum antibody titers from vaccination with
iVN04 and VN04 ca.
Group Vaccine dose
GMT Nt antibody
against VN04 ca virus
Prime Boost
Post
dose 1
Post dose
2
1P B S P B S ,10 ,10
2 iVN04 PBS ,10 ,10
3 iVN04 iVN04 ,10 ,10
4 iVN04 VN04 ca ,10 95
5V N 0 4 ca PBS 51 20
6V N 0 4 ca iVN04 62 160
7V N 0 4 ca VN04 ca 62 123
8 iVN04/TiterMax VN04 ca 48 190
Ferrets were inoculated with 10
7 PFU of VN04 ca intranasally or 15 mg of iVN04
vaccine intramuscularly. Blood was collected 4 weeks after each dose and the
H5N1-specific antibody levels (expressed as geometric mean titers) were
determined by microneutralization assay.
doi:10.1371/journal.pone.0021942.t001
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levels of HA-specific IgA serum titers while DNA vaccination
alone induced very modest levels of HA-specific IgA antibody
(Figure 2B). Interestingly, both the H5 HA-specific serum IgG and
IgA titers elicited by the various vaccine regimens declined four
weeks after the boost. This decrease in influenza-specific antibody
titers has also been described previously for a seasonal H3N2
strain in mice [29]. In contrast to binding antibodies, the serum Nt
Ab titers remained at comparable levels between two and four
weeks after the boost (Figure 2C).
The levels of HA-specific antibodies in immunized ferret sera
were also measured by microneutralization assay (left panel) and
HAI assay (right panel, Figure 3). The breadth of the serum Nt
and HAI Ab titers against antigenically distinct H5N1 influenza
A/Hong Kong/213/2003 from clade 1 (HK03), A/Anhui/1/
2005 from clade 2.3.4 (AH05), and A/Indonesia/5/2005 from
clade 2.1 (IN05) ca strains was also examined. Ferrets that were
primed with VN04 ca virus displayed low levels of serum Nt Ab
titers against the homologous vaccine virus 4 weeks post-
immunization (Groups 2 and 3, Figure 3A, left panel) while
ferrets that were primed with the H5 HA DNA exhibited barely
detectable serum Nt Ab at the same time point (Groups 4 and 5).
Ferrets that received 2 doses of VN04 ca virus (Group 2) or those
that received the prime-boost regimen (Groups 3 and 4) had
higher serum Nt Ab titers. Three doses of the H5 HA DNA
vaccine elicited a low level of serum Nt Ab titers (Group 5). A very
similar pattern of results was also observed for serum HAI Ab
against the VN04 ca virus (Figure 3A, right panel).
The prime-boost strategies (Groups 3 and 4, Figure 3) induced
serum Nt and HAI Ab titers that cross reacted to the variant
H5N1 viruses tested in this study at levels comparable to that
elicited by two doses of VN04 ca virus (Group 2). In contrast,
ferrets that were immunized with the H5 HA DNA vaccine alone
exhibited barely detectable Ab titers against AH05 and IN05 and
low serum Nt Ab titers to HK03 (Group 5, Figure 3C, 3D and 3B,
respectively).
Figure 1. H5 HA DNA vaccine construct. (A) Schematic diagram of H5-VN.tPA HA gene. The H5-VN.tPA DNA encodes the full length HA antigens
with a human tissue plasminogen activator (tPA) leader substituting for the natural HA leader sequence. The cleavage site between HA1 and HA2
subunits are indicated. The numbers above the HA inserts denote the relevant amino acid positions in natural HA proteins. (B) Western-blot analysis
of the expression of HA antigen by H5-VN.tPA DNA vaccine in transiently transfected 293T cell supernatant (S) and cell lysate (L).
doi:10.1371/journal.pone.0021942.g001
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response to variant H5N1 viruses would confer protection in vivo
(Figure 4). All immunized ferrets were challenged with the HK03
ca vaccine virus. Because of the attenuated phenotype of this
challenge virus, viral replication could only be measured in the
upper respiratory tract of ferrets. Ferrets that either received two
doses of the VN04 ca virus or those that were primed with H5 HA
DNA followed by VN04 ca virus boost were completely protected
from HK03 ca virus replication in the nasal turbinates (Groups 2
and 4, p,0.05). The group that was primed with VN04 ca virus
and boosted with H5 HA DNA also had significantly reduced viral
titers in the upper respiratory tract (Group 3, p ,0.05). The ferrets
that received H5 HA DNA vaccine alone (Group 5) were not
protected against HK03 ca virus replication; viral titer in the NT
was similar to the vector control group (Group 1). Thus, similar to
two doses of VN04 ca vaccination, H5 HA DNA prime-VN04 ca
Figure 2. Kinetics of the development of H5 HA-specific serum IgG (A), IgA (B), and neutralizing antibodies (C) elicited by various
H5N1 prime-boost regimens. Ferrets were immunized with either 10
7 PFU of VN04 ca virus (weeks 0 and 4) or 200 mg of H5 HA DNA (weeks 0, 2
and/or 4) and serum samples were collected regularly at 2-week intervals. H5 HA-specific IgG and IgA in ferret serum samples (N=4/group) were
determined by ELISA using recombinant VN04 H5 HA as antigen. Neutralizing antibody titers against 100 TCID50 of the VN04 ca virus are depicted.
Geometric mean titers from each group are shown.
doi:10.1371/journal.pone.0021942.g002
H5 HA DNA Prime and LAIV Boost in Ferrets
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21942Figure 3. Serum antibody titers against homologous and variant H5N1 ca viruses following different vaccine regimens in ferrets.
Ferrets (N=4/group) were inoculated with 10
7 PFU of VN04 H5N1 ca intranasally or 200 mg of vector or H5 HA DNA vaccine intramuscularly as
indicated. Blood was collected 4 weeks after each dose and H5N1-specific antibody titers in the serum were determined by microneutralization (left
panel) and HAI (right panel) assays. Geometric mean titers of neutralizing and HAI Ab against (A) VN04 (A/Vietnam/1203/2004), (B) HK03 (A/Hong
Kong/213/2003), (C) AH05 (A/Anhui/1/2005), and (D) IN05 (A/Indonesia/5/2005) ca viruses are depicted. Data points in black indicate titers of post-
prime and data points in orange indicate titers of post-boost and the mean Ab titers are indicated in horizontal solid lines. The dashed line indicates
the detection limit of the assays.
doi:10.1371/journal.pone.0021942.g003
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protection against homologous and heterologous H5N1 virus.
Discussion
The recent experience with the novel swine-origin 2009 H1N1
virus highlighted the importance of early, swift delivery and broad
administration of vaccines during a pandemic. In the case of
pH1N1 vaccine, a single dose without an adjuvant was highly
immunogenic in adults and induced ,90% seroprotective
conversion rate [30,31]. This is most likely due to the pre-existing
cross-reactive antibodies to pH1N1 present in humans, especially
the older adults who were previously exposed to seasonal H1N1
viruses [31,32]. However, many populations lack any pre-existing
immunity against the novel H5N1 viruses that have sporadically
infected humans. Thus, priming might be an important strategy to
reduce the mortality and morbidity caused by the HPAI H5N1
viruses.
Unlike the 2009 H1N1 virus that has binding specificity for both
a2,6-linked (human-like) and a2,3-linked (avian-like) sialic acid
(SA) receptors [33,34], the H5N1 VN04 ca virus has binding
preference for the a2,3-linked SA receptor [35]. The receptor
binding preference of the H5N1 viruses may contribute to their
inefficient transmission among humans and the low seropreva-
lence to this virus subtype among presumably exposed populations
[36,37,38]. In addition, the glycosylation of the HA protein at
position 158 also contributed to the low immunogenicity of VN04
ca [35]. Thus, priming susceptible populations with a pre-
pandemic H5 vaccine would induce some cross-protective
antibodies that could significantly augment the immunogenicity
of an antigenically matched pandemic vaccine once it becomes
available. The rapid immune response elicited by the pandemic
vaccine, acting as a boosting agent, is expected to reduce the
morbidity, mortality and transmission of the pandemic virus [33]
and may decrease the number of doses required to achieve
protective immunity.
In this study, the immunogenicity of the different vaccine
regimens was assessed primarily by measuring HAI and Nt Ab in
the serum of immunized ferrets. Although it is well established that
LAIVs induce a robust mucosal immune response, we were unable
to detect H5 HA-specific IgG and IgA antibody titers in the nasal
wash due to assay insensitivity using the existing available ferret
reagents in the ELISA assay. Two doses of iVN04 were not
immunogenic in seronegative ferrets, consistent with the findings
that purified protein antigens are not immunogenic in naı ¨ve
animals [27]. However, priming with an adjuvanted iVN04 or
VN04 ca virus could elicit high serum Nt Ab titers after the boost
by either iVN04 or VN04 ca virus. These findings are in
agreement with previous reports that adjuvants significantly
improve the immunogenicity of inactivated H5N1 vaccines
[39,40]. However, adjuvanted influenza vaccines are currently
not licensed for use in the United States. Concerns over possible
genetic reassortment with circulating influenza virus strains also
restrict the use of an H5N1 LAIV for priming. Therefore, an
alternative priming strategy is needed for future pandemics that
are caused by novel subtypes. We found that a codon-optimized
H5 HA DNA vaccine was comparable to an adjuvanted iVN04 as
a priming agent. H5 HA DNA vaccination was not effective when
administered alone by needle injection, inducing serum Nt or HAI
Ab at levels below the detection limits. Our previous experience
indicated that DNA immunization by intramuscular injection was
not robust; thus, an additional DNA immunization was admin-
istered 2 weeks after the first dose in this study. This extra DNA
dose did not appear to enhance DNA vaccine-mediated antibody
response. However, the H5 HA DNA vaccine can prime the
immune system to rapidly mount an immune response after
boosting with VN04 ca virus vaccine, reaching serum Nt Ab titers
comparable to that elicited by two doses of the live attenuated
VN04 ca vaccine. The H5 HA DNA vaccine is an attractive
alternative over an adjuvanted iVN04 because the DNA can be
produced quickly, is relatively inexpensive to manufacture, and is
amenable to long-term stockpiling.
Figure 4. Protection conferred by different H5 vaccine prime-boost regimens in ferrets. Four weeks after boost immunization, ferrets
were intranasally infected with 10
7 PFU of HK03 ca virus. Nasal turbinates were collected on day 3 post-infection and viral titers in tissue
homogenates were determined by EID50. Horizontal lines depict the mean virus titers for each group. An asterisk above a horizontal bar denotes
statistical significance compared to the vector DNA group (p,0.05, Mann-Whitney U Test).
doi:10.1371/journal.pone.0021942.g004
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domestic fowl [41]. It is highly desirable to produce a vaccine that
is broadly cross-reactive to diverse strains. Ferrets that received 2
doses of VN04 ca virus or the H5 HA DNA prime-VN04 ca virus
boost regimen had serum Nt and HAI Ab responses against
antigenically distinct H5N1 viruses from different clades and
prevented replication of a heterologous HK03 ca vaccine virus.
Our previous results indicate that mice immunized with a single
dose of the VN04 ca vaccine were protected from various lethal
doses of heterologous H5N1 wt viruses even in the absence of
detectable Nt Ab in the serum, through a yet undefined immune
mechanism [12]. Thus, the correlation between serum HAI or Nt
Ab titers and protection from either lethal virus challenge or even
virus replication in the respiratory tract of animals for H5N1
viruses is not firmly established. In this study, the ferrets that
received the VN04 ca vaccine (whether as a prime or as a boost)
with detectable serum Nt and HAI Ab against antigenically diverse
H5N1 viruses are expected to survive a lethal HPAI H5N1 virus
challenge based on our previous report [12]. It was recently
reported that priming with H1 HA DNA is associated with the
induction of a broader Nt Ab response to temporally distant H1N1
strains and these Nt Ab target the conserved HA stem region [23].
Sera from ferrets that received either two doses of VN04 ca virus or
the H5 HA DNA prime-VN04 ca virus boost regimen also
recognized the HA2 region of a recombinant H5 HA and the H1
HA protein of a seasonal H1N1 virus, A/South Dakota/6/2007,
by Western blotting (data not shown). We were not able to
demonstrate clear broader reactivity against H5N1 subtypes of the
animals primed with DNA followed by boost with the VN04 ca
virus. Even though H5 HA DNA vaccination elicited these HA2-
binding antibodies, they were not sufficient to protect ferrets from
replication of a heterologous H5N1 virus. Additional studies are
required to determine the contributions of the stalk region-
mediated response to subtypic and heterosubtypic immunity. It
will also be important to understand the mechanism of protection
induced by DNA vaccination and the contribution of cell-
mediated immune responses to this protection.
Several strategies could be considered to further broaden the
immune response elicited by H5 HA DNA priming by using
heterologous H5 HA from genetically distinct clades or with
multiple H5 HA DNA plasmids from representative H5N1 clades
followed by boosting with the antigenically matched pandemic
LAIV vaccine strain once it becomes available. A robust immune
response towards the boosting strain can be achieved even when
the doses are administered months or years apart [42,43,44]. A
similar study is warranted to determine the durability of an H5 HA
DNA priming so that the timing of additional doses could be
planned. While the duration of protection conferred by the
pandemic LAIV boost is not known, recent studies in children
immunized with the seasonal trivalent LAIV show that relative
efficacies against antigenically matched and mismatched strains
can last more than 12 months post-vaccination [45,46]. Another
option to improve the immunogenicity of H5 HA DNA priming is
to adopt a more efficient gene delivery method such as the use of a
gene gun or electroporation [47]. However, the accessibility,
affordability, safety, and ease of operating such devices for DNA
vaccine delivery may limit their use, especially in a pandemic
setting [48]. In the current study, DNA priming with conventional
needle injection was proven effective. However, we only evaluated
H5N1 vaccines in ferrets. The effectiveness of the DNA priming
effect remains to be demonstrated for other influenza virus
subtypes in pre-clinical studies; its safety and efficacy should be
further evaluated in clinical studies.
Materials and Methods
Generation of recombinant vaccine viruses
Recombinant influenza VN04, HK03, IN05 and AH05 ca
viruses with multi-basic amino acids removed from the H5 HA
cleavage site were generated as described previously [12].
Recombinant 6:2 viruses bearing the modified HA and unmod-
ified NA from each H5N1 virus along with the six internal protein
gene segments of AA ca were rescued using the eight-plasmid
transfection system [11,49]. Viruses were amplified in the allantoic
cavity of 10–11 day old embryonated chicken eggs. Viral titer was
determined by plaque assay or 50% tissue culture infectious dose
(TCID50) in Madin-Darby canine kidney (MDCK) cells.
Codon-optimized H5 HA DNA vaccines
The codon optimized H5-VN.tPA DNA expressing the full
length HA0 was cloned into DNA vaccine vector pSW3891 under
a human tissue plasminogen activator (tPA) leader sequence. The
DNA vaccine plasmid was prepared from Escherichia coli (HB101
strain) with a Mega purification kit (Qiagen, Valencia, CA) for
both in vitro transfection and in vivo animal immunization studies.
The HA protein expression was examined by transient transfec-
tion of 293T cells and Western blot analysis as previously
described [28].
Ferret studies
Eight- to ten-week old ferrets from Simonsen (Gilroy, CA) that
were seronegative for antibodies to seasonal H1N1, H3N2 and
H5N1 ca viruses were used in the studies. All animals were
anesthetized with isoflurane prior to immunization. In the first
experiment, 8 groups of 4 ferrets were primed with bilateral intra-
muscular (i.m.) injections of one of the following: (1) PBS; (2) 15 mg
of iVN04 (NR-4143, Biodefense and Emerging Infections
Research Resources Repository, NIAID, NIH, Bethesda, MD);
(3) 15 mg of iVN04 with the adjuvant TiterMax (TiterMax, USA);
or (4) intra-nasally (i.n.) with 10
7 PFU of VN04 ca virus. Four
weeks after the first dose, ferrets were immunized with PBS,
iVN04 or VN04 ca virus. H5 HA-specific antibody responses were
evaluated using sera collected on days 28 and 56 post-vaccination.
In the second experiment, 5 groups of 4 ferrets were vaccinated
with bilateral i.m. injections of one of the following: (1) 200 mgo f
plasmid vector (Group 1); (2) i.n. inoculation of 10
7 PFU of VN04
ca virus (Groups 2–3) or (3) codon-optimized H5 HA DNA
plasmid (Groups 4–5). Two weeks after priming, a group of ferrets
that were primed with the H5 HA DNA vaccine received a second
dose of the H5 HA DNA vaccine. Four weeks after the first dose,
ferrets were immunized with PBS, H5 HA DNA or VN04 ca virus.
Four weeks after the boost, all ferrets were i.n.-infected with 10
7
PFU of HK03 ca virus. Ferrets were sacrificed on day 3 post-
infection, the nasal turbinates were harvested and virus titers in the
upper respiratory tract of ferrets was determined by 50% egg
infectious dose (EID50) assay and expressed as log10 EID50/g of
tissue. H5 HA-specific antibody responses were evaluated using
sera collected on days 14, 28, 42 and 56 post-vaccination. All
animal studies were conducted in accordance with the Institutional
Animal Care and Use Committee-approved protocols (058-07-035
and 081-09-053).
HAI and microneutralization assays
Influenza-specific serum antibody responses against the homol-
ogous and heterologous H5N1 viruses of immunized ferrets were
determined by microneutralization assay and HAI assay. Briefly,
serum samples were treated with receptor-destroying enzyme
(Denka-Seiken, Tokyo, Japan) at 37uC overnight followed by heat-
H5 HA DNA Prime and LAIV Boost in Ferrets
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dilutions of serum were incubated with an equal volume of 4 HA
units of the indicated H5N1 ca viruses in a 96-well V-bottom plate
for 1 hr, followed by the addition of either 1.0% horse erythrocytes
(Lampire Biological Laboratories, Pipersville, PA) containing 0.5%
BSA (against VN04, AN05 and IN05) or 0.5% turkey erythrocytes
(Lampire Biological Laboratories, Pipersville, PA) (against HK03).
HAI antibody titers were defined as the reciprocal of the highest
serum dilution that completely inhibited hemagglutination. For
microneutralization assays, serial 2 fold-dilutions of serum were
incubated with an equal volume of 100 TCID50 of the indicated
H5N1 ca viruses at 33uC for 1 hr. The virus-serum mixture was
then transferred to monolayers of MDCK cells and incubated at
33uC for 6 days. Neutralizing antibody titer was defined as the
reciprocal of the highest dilution of serum that completely
neutralized virus infectivity as indicated by the absence of
cytopathic effects (CPE) on day 6 post-infection.
ELISA
An enzyme-linked immunosorbent assay (ELISA) was conduct-
ed to measure H5 HA-specific IgG and IgA antibody titers in the
sera of immunized ferrets. Half of a 96-well flat bottom plate
(Costar, Corning, NY) were coated with 0.05 mg of recombinant
VN04 H5 HA protein (Protein Sciences, Meriden, CT) and the
other half of the plates were incubated with 100 ml of PBS. The
plates were incubated at 4uC overnight, washed 3x with PBS
containing 0.05% Tween 20 (Sigma, St. Louis, MO), and then
blocked with 300 ml of blocking buffer (SuperBlock blocking buffer
in PBS, ThermoScientific, Rockford, IL) for 1 hr at 37uC. After
removing the blocking buffer from the plates, serial 4-fold dilutions
of serum samples (in 10% SuperBlock blocking buffer + 0.05%
Tween 20; for IgG assay) or serial 2-fold dilutions of serum
samples (for IgA assay) were added to the wells with or without the
coating antigen, and incubated for 1 hr at 37uC. After washing,
the plates were incubated with 100 ml of 1:10,000 dilution (in 10%
SuperBlock + 0.05% Tween 20) of goat anti-ferret IgG conjugated
to horse radish peroxidase (Bethyl Laboratories, Inc., Montgom-
ery, TX) (for IgG assay) or 100 ml of 1:2,500 dilution of goat anti-
ferret IgA (Bethyl Laboratories, Inc., Montgomery, TX) conju-
gated to biotin (EZ-link Sulfo-NHS-SS biotinylation kit, Thermo-
Scientific, Rockford, IL) (for IgA assay) for 45 min at 37uC. After
washing, the IgA plates were further incubated with 1:10,000
dilution of streptavidin-HRP (ThermoScientific, Rockford, IL) for
30 min at 37uC. Both IgG and IgA assay plates were developed
with 100 ml of 3,39,5,59 tetramethylbenzidene (TMB) substrate
solution (Sigma, St. Louis, MO); IgG plates were incubated for
5 min at room temperature while IgA plates were incubated for
30 min at 37uC. The reactions were stopped by adding 100 mlo f1
NH 2SO4 and the absorbance were read at l=450 nm. The
difference in the OD readings of each diluted sample between
wells coated with or without the H5 HA antigen was determined,
and the H5 HA-specific IgG and IgA titers were defined as the
reciprocal of the highest dilution that gave a DOD value $ 0.200.
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